for residual tnbc post-chemo, capecitabine should be offered
Published 2 years ago • 6.2K plays • Length 4:28Download video MP4
Download video MP3
Similar videos
-
4:01
capecitabine remains the adjuvant standard of care for tnbc with residual disease | ingrid mayer
-
0:37
management for residual disease in tnbc after chemo-immunotherapy
-
1:32
comparing data for capecitabine after neoadjuvant chemotherapy in tnbc
-
1:27
what to do in patients with early-stage tnbc who have not achieved a pcr?
-
8:22
the immune landscape of residual tnbc after neoadjuvant chemotherapy
-
6:54
no pcr in patients after neoadjuvant chemotherapy in tnbc
-
1:22
immunological signatures to predict outcomes in patients with tnbc
-
1:16
tackling residual disease in breast cancer
-
1:25
dr. goetz on adjuvant capecitabine following neoadjuvant chemotherapy and surgery
-
5:47
the meaning of residual disease in breast cancer
-
33:30
neelima denduluri, md -- treatment of triple negative breast cancer
-
20:24
neoadjuvant chemotherapy for breast cancer - time to rethink. 27jul22
-
12:40
chemotherapy update - xeloda | our journey
-
0:42
can anthracyclines be omitted in tnbc?
-
5:46
value of circulating tumor dna after neoadjuvant chemotherapy for triple negative breast cancer
-
3:36
next step - adjuvant therapy - chemo pill - xeloda | our journey
-
0:54
oncology appointments for metastatic triple negative breast cancer #tnbc #breast cancer #radiation
-
21:36
treatment planning for triple negative breast cancer | 2022 evolution conference
-
0:27
tnbc in black women